-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This article is original by Translational Medicine.
Please indicate the source Author: Sibyl Introduction: Due to the mutation of the new coronavirus, the monoclonal antibody therapy of GlaxoSmithKline and Vir Biotechnology has recently been suspended
.
Researchers have begun to look for ways to fight the new coronavirus in different ways, hoping to no longer fail in the face of emerging variants
.
The three antiviral drugs currently approved to directly act on the new coronavirus are: Gilead's Veklury, Pfizer's Paxlovid and Merck's molnupiravir, which can inhibit the activity of a key component of the virus
.
So far they have worked for every relevant variant
.
But researchers warn that drug resistance could become a problem as the drug becomes more widely available
.
So researchers have been looking for small molecules that can affect human proteins, not viruses
.
Viruses need to attach to certain proteins in human cells in order to enter cells and multiply
.
The so-called host-directed therapy is to prevent the virus from invading by inhibiting the activity of these proteins
.
In theory, if the treatment we choose does not act directly on the virus, the chances of the virus developing resistance will be less
.
On Monday (March 28), researchers at the University of British Columbia and Cornell University's School of Veterinary Medicine published a new study in Nature
.
Titled "A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic"
.
A small molecule known as N-0385 "shows high levels of preventive and therapeutic efficacy after one or more administrations
.
" https:// The researchers positioned N-0385 as an early potential treatment option for VOCs (volatile organic compounds) with "complete protection" against death caused by the virus, including the Delta variant
.
It can also prevent symptoms such as weight loss, lung disease, and viral infections
.
The researchers said N-0385 could "reduce the risk of antiviral resistance mutations.
"
They believe that N-0385 can not only be used as a treatment for those who have not been vaccinated against the new crown, those at high risk of exposure to the new crown, and critically ill patients, but also as a drug against "future emerging pathogens (such as influenza)"
.
This antiviral substance is a protease inhibitor of TMPRSS2
.
TMPRSS2 is a type II transmembrane serine protease that helps cleave those viral spike proteins that help the virus enter cells
.
The researchers said that no mutation of the TMPRSS2 cleavage site has been found in the new coronavirus variant
.
The researchers emphasized that the continued need for new coronavirus treatment options, especially the emergence of new sub-variants leading to a resurgence of cases, means that the pandemic "remains a significant threat to global health for the foreseeable future
.
"
However, this does not mean that biopharmaceutical companies will automatically develop new crown drugs
.
Some companies, including Alnylam and Capricor Therapeutics, have pulled out of the field as existing viral treatments remain effective
.
While the peer-reviewed manuscript has been published ahead of schedule, the editors of Nature have also issued a warning: "We are providing an unedited version of this manuscript for the early publication of this research
.
Before final publication The manuscript will undergo further editing before
.
Please note that there may be some errors in the manuscript that affect the content, the above applies to all legal disclaimers
.
" Reference: https://endpts.
com/researchers-point-to-a- host-directed-covid-19-antiviral-that-could-be-combined-with-existing-pandemic-treatments/ Note: This article is intended to introduce medical research progress and cannot be used as a reference for treatment plans
.
For health guidance, please go to a regular hospital for treatment
.
Recommendation·Event Click the text to view the details.
March 30th 19:00-21:00 Online Seminar on Frontier Progress of Proteomics and Prospects of Innovative Technologies March 31st 19:00-21:00 Sharing Global Technology Online| Oncology Precision Diagnosis Innovation and Development Webinar April 13th 19:00-21:00 Online Innovative Drug R&D and Research and Development Salon (coming soon) April 14th 15:00-16:20 Online based on real-time living cells Imaging-based targeted tumor therapy (to be announced soon) April 20, 09:00-18:00 How to improve the efficiency of new macromolecular drug research and development from basic experiments (to be announced soon)
Please indicate the source Author: Sibyl Introduction: Due to the mutation of the new coronavirus, the monoclonal antibody therapy of GlaxoSmithKline and Vir Biotechnology has recently been suspended
.
Researchers have begun to look for ways to fight the new coronavirus in different ways, hoping to no longer fail in the face of emerging variants
.
The three antiviral drugs currently approved to directly act on the new coronavirus are: Gilead's Veklury, Pfizer's Paxlovid and Merck's molnupiravir, which can inhibit the activity of a key component of the virus
.
So far they have worked for every relevant variant
.
But researchers warn that drug resistance could become a problem as the drug becomes more widely available
.
So researchers have been looking for small molecules that can affect human proteins, not viruses
.
Viruses need to attach to certain proteins in human cells in order to enter cells and multiply
.
The so-called host-directed therapy is to prevent the virus from invading by inhibiting the activity of these proteins
.
In theory, if the treatment we choose does not act directly on the virus, the chances of the virus developing resistance will be less
.
On Monday (March 28), researchers at the University of British Columbia and Cornell University's School of Veterinary Medicine published a new study in Nature
.
Titled "A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic"
.
A small molecule known as N-0385 "shows high levels of preventive and therapeutic efficacy after one or more administrations
.
" https:// The researchers positioned N-0385 as an early potential treatment option for VOCs (volatile organic compounds) with "complete protection" against death caused by the virus, including the Delta variant
.
It can also prevent symptoms such as weight loss, lung disease, and viral infections
.
The researchers said N-0385 could "reduce the risk of antiviral resistance mutations.
"
They believe that N-0385 can not only be used as a treatment for those who have not been vaccinated against the new crown, those at high risk of exposure to the new crown, and critically ill patients, but also as a drug against "future emerging pathogens (such as influenza)"
.
This antiviral substance is a protease inhibitor of TMPRSS2
.
TMPRSS2 is a type II transmembrane serine protease that helps cleave those viral spike proteins that help the virus enter cells
.
The researchers said that no mutation of the TMPRSS2 cleavage site has been found in the new coronavirus variant
.
The researchers emphasized that the continued need for new coronavirus treatment options, especially the emergence of new sub-variants leading to a resurgence of cases, means that the pandemic "remains a significant threat to global health for the foreseeable future
.
"
However, this does not mean that biopharmaceutical companies will automatically develop new crown drugs
.
Some companies, including Alnylam and Capricor Therapeutics, have pulled out of the field as existing viral treatments remain effective
.
While the peer-reviewed manuscript has been published ahead of schedule, the editors of Nature have also issued a warning: "We are providing an unedited version of this manuscript for the early publication of this research
.
Before final publication The manuscript will undergo further editing before
.
Please note that there may be some errors in the manuscript that affect the content, the above applies to all legal disclaimers
.
" Reference: https://endpts.
com/researchers-point-to-a- host-directed-covid-19-antiviral-that-could-be-combined-with-existing-pandemic-treatments/ Note: This article is intended to introduce medical research progress and cannot be used as a reference for treatment plans
.
For health guidance, please go to a regular hospital for treatment
.
Recommendation·Event Click the text to view the details.
March 30th 19:00-21:00 Online Seminar on Frontier Progress of Proteomics and Prospects of Innovative Technologies March 31st 19:00-21:00 Sharing Global Technology Online| Oncology Precision Diagnosis Innovation and Development Webinar April 13th 19:00-21:00 Online Innovative Drug R&D and Research and Development Salon (coming soon) April 14th 15:00-16:20 Online based on real-time living cells Imaging-based targeted tumor therapy (to be announced soon) April 20, 09:00-18:00 How to improve the efficiency of new macromolecular drug research and development from basic experiments (to be announced soon)
